Stabilized Helical Peptides for HIV Assembly Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV assembly inhibitors, such as CAI, are unable to penetrate cells, limiting their effectiveness as in vivo treatments due to their inability to enter infected cells.
Innovation Solution
Development of α-helical peptides with cross-linking procedures that increase α-helicity, allowing them to penetrate cells and function as active inhibitors of HIV assembly by stabilizing the peptide structure using unnatural amino acids with olefinic groups, forming a cross-link between them.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If linear peptide CAI is used to inhibit HIV-1 assembly, then antiviral activity is achieved, but cell penetration ability is lost
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical properties of the peptide through cross-linking. The cross-linking procedure increases the α-helicity parameter of the peptide, transforming it from a linear flexible structure to a stabilized helical structure. This structural parameter change enables the peptide to penetrate cells while maintaining its antiviral activity against HIV-1 assembly.
Solution Approach 2:
The patent creates a composite structure by incorporating unnatural amino acids with olefinic groups into the peptide sequence. These modified amino acids form cross-links that create a composite molecular structure combining the antiviral properties of the original peptide with the cell-penetrating capabilities of the cross-linked helical framework.
2Ease of operation
If cross-linking procedures are applied to increase α-helicity, then cell penetration ability is improved, but peptide structure complexity increases
Solution Approach 1:
The patent applies local quality by introducing cross-links at specific positions within the peptide sequence rather than throughout the entire structure. The unnatural amino acids with olefinic groups are placed at predetermined locations to form localized cross-links that stabilize the helical structure without creating excessive complexity throughout the entire peptide.
Solution Approach 2:
The patent employs preliminary action by pre-designing the peptide sequence with unnatural amino acids positioned to form cross-links. The cross-linking capability is built into the peptide structure during synthesis, so the stabilizing effect is already in place before the peptide needs to function, eliminating the need for complex post-synthesis modifications.
3Stability of the object's composition
If unnatural amino acids with olefinic groups are incorporated, then peptide stability is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the peptide synthesis into modular components. The unnatural amino acids with olefinic groups are synthesized and incorporated as discrete units at specific positions in the sequence. This modular approach allows each component to be optimized independently and assembled into the final stable peptide structure, simplifying the overall manufacturing process despite the complexity of the individual components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilized peptides effectively inhibit both immature and mature HIV-1 particles in vitro and in vivo, demonstrating enhanced cell penetration and antiviral potency, thereby addressing the limitation of previous inhibitors.
Implementation Method 1
the two olefinic groups of the unnatural amino acids are on the same side of the α-helix and are joined to form a cross-link between the two unnatural amino acids
Data Source
AI summary
Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.